Zelira in the news

Articles

For media related enquiries please contact Damien Carbon at Profile Media
Ph: +61 (0) 412 332 122 E: damienc@profilemedia.com.au

Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCMKTS:ZLDAF) final clinical report for a Phase 1 dose escalation trial in chronic pain patients on long-term high-dose opioid treatment shows that the primary and secondary endpoints for safety and efficacy were met.

Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints

Start typing and press Enter to search

Shopping Cart